Pharmaceuticals
Innovent and IASO Bio Enhance Strategic Collaboration in Cell Therapy
SAN FRANCISCO and SUZHOU, China, July 5, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic,...
2024-07-05 16:30
4674
Biostar Pharma Announces FDA Clearance of the IND Application for a Phase 2 Study of Utidelone Injection (UTD1) in HER2- Breast Cancer Brain Metastasis
SAN FRANCISCO, July 5, 2024 /PRNewswire/ -- Biostar Pharma, Inc., the U.S. subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. (Biostar), which is a synthetic biology-driven biopharma company focusing on the development and commercialization of innovative oncology drugs, announced today that ...
2024-07-05 16:07
1477
Zhejiang Doer Biologics Completes Enrollment of the Phase 1b/2a Trial Evaluating DR10624 in Obese Subjects with Modest Hypertriglyceridemia
HANGZHOU, China, July 5, 2024 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that the company has completed the enrollment in the Phase1b/2a trial ...
2024-07-05 15:56
3471
LOTTE BIOLOGICS Holds Groundbreaking for Songdo Bio Campus
* Plans to Join the Ranks of the TOP 10 Global CDMOs, Heralding a New Era in the Global CDMO Landscape SEOUL, South Korea, July 3, 2024 /PRNewswire/ -- In a landmark event signaling its ambitious foray into the biopharmaceutical sector, LOTTE BIOLOGICS, under the leadership of CEORichard W. Lee...
2024-07-04 11:17
2516
Ascentage Pharma Received US$100 Million Option Payment from Takeda
ROCKVILLE, Md. and SUZHOU, China, July 4, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for hematological malignancies, announced today that onJuly 2, 2024,...
2024-07-04 08:28
4269
/C O R R E C T I O N -- Menarini Silicon Biosystems/
In the news release, Menarini's cell based non-invasive prenatal technology demonstrates high resolution detection of fetal genomic abnormalities from a simple maternal blood draw, issued02-Jul-2024 by Menarini Silicon Biosystems over PR Newswire, we are advised by the company that the subheadlin...
2024-07-03 03:24
2924
Bloomage Ranks on World Brand Lab's China 500 Most Valuable Brands List
PARSIPPANY, N.J., July 2, 2024 /PRNewswire/ -- Bloomage has once again ranked on the "China's 500 Most Valuable Brands" list by World Brand Lab, a premier global brand value evaluation agency. This milestone not only affirms the strength of Bloomage's brand but also recognizes its long-term commi...
2024-07-02 21:00
1537
PharmAbcine's Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration Advances to Both Single-dose of 4mg and Multiple-dose of 3mg
* Safety Review Committee (SRC) approves single 3mg dose for the third cohort in Phase 1 trial of PMC-403 DAEJEON, South Korea, July 2, 2024 /PRNewswire/ -- PharmAbcine, Inc. ("PharmAbcine" or the "Company") (KOSDAQ:208340), a clinical-stage public company developing next generation therapeutic...
2024-07-02 11:02
2154
HiRO acquires CRO DeltaMed Solutions, continues to expand cross-border operations in the US
WILMINGTON, Del., July 2, 2024 /PRNewswire/ -- Harvest Integrated Research Organization (HiRO), a full-service, boutique global CRO, is excited to announce its latest strategic move with the successful acquisition of DeltaMed Solutions, an emerging CRO with a robust foothold in the US. The acquis...
2024-07-02 10:00
3422
Innovent Announces Oral Presentation at the ESMO Gastrointestinal Cancers Congress 2024 on Latest Clinical Data of Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
SAN FRANCISCO and SUZHOU, China, July 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...
2024-07-02 08:00
3565
Altos Biologics Files for Approval of Aflibercept Biosimilar
DAEJEON, South Korea, July 1, 2024 /PRNewswire/ -- Alteogen Inc.
2024-07-02 08:00
2797
Bridgewest Perth Pharma gains strategic edge with noted Australian Executive John Van Der Wielen on Board
PERTH, Australia, July 2, 2024 /PRNewswire/ -- Bridgewest Perth Pharma, global pharmaceutical holding company withNovaCina CDMO division and LumaCina pharmaceutical supply division, announces the addition of renown Australian executiveJohn Van Der Wielen to Board of Directors. Van Der Wielen will...
2024-07-02 07:00
2092
IASO Bio Presented Clinical Data and Single-cell Analysis of Equecabtagene Autoleucel for the Treatment of Central Nervous System Autoimmunity in Oral Presentation at EAN Congress 2024
SHANGHAI, NANJING, CHINA, and SAN JOSE, Calif., July 1, 2024 /PRNewswire/ -- IASO biotechnology ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, presented the clinical data and single-cell an...
2024-07-01 15:43
1484
SCG Cell Therapy Announces FDA IND Clearance of SCG142, a next-generation HPV-specific TCR T cell therapy for patients with HPV-associated solid tumors
SINGAPORE, July 1, 2024 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, today announced that U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) appl...
2024-07-01 10:56
1992
Pierre Fabre Laboratories announce granting of European marketing authorization for OBGEMSA™ (vibegron) in overactive bladder.
CASTRES, France, June 28, 2024 /PRNewswire/ -- The European Commission (EC) has authorized the marketing of OBGEMSA™ (vibegron) by Pierre Fabre Laboratories for the symptomatic treatment of overactive bladder syndrome in adults, a particularly debilitating condition affecting over 70 million pati...
2024-06-28 23:55
3346
Comprehensively Covering Multiple Myeloma: IASO Bio's GPRC5D CAR-T Product RD118 Receives IND Approval from NMPA
NANJING, China, SHANGHAI and SAN JOSE, Calif., June 28, 2024 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing, and marketing innovative cell therapies and antibody products, today announces thatthe investigational new d...
2024-06-28 18:59
2148
Hasten Announces Acquisition of 14 Celltrion Legacy Products, Accelerating its Business Expansion in the Pan-Asia Area
SHANGHAI, June 28, 2024 /PRNewswire/ -- Hasten Biopharmaceutical Co., Ltd. (referred to as "Hasten") announced today that it has successfully acquired the asset rights of 14 branded products across Pan-Asia countries and regions from Celltrion, a Korean biopharmaceutical company. According to the...
2024-06-28 16:26
7093
Sirnaomics Announces Completion of STP707 Phase I Clinical Study with Strong Safety Profile and Disease Activity for the Treatment of Pancreatic Cancer Patients
HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 28, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or " Sirnaomics"; stock code: 2257), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, toda...
2024-06-28 13:44
2408
Innovent Provides Interpretation and Updates on Clinical Data from Mazdutide GLORY-1 Study and General Biomedicine Pipeline
SAN FRANCISCO and SUZHOU, China, June 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ...
2024-06-28 08:00
2512
US FDA New Drug Application Approval of Ohtuvayre™ (ensifentrine) for the Maintenance Treatment of COPD
SHANGHAI, June 27, 2024 /PRNewswire/ -- Nuance Pharma's global partner Verona Pharma plc (Nasdaq: VRNA), announces the US Food and Drug Administration ("FDA") approved Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. Ohtuvay...
2024-06-27 13:59
2163
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
7433
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
6834
